Results 21 to 30 of about 48,011 (239)

Prevalence and Specificity of Anti-HPA and Anti-HLA Antibodies in Patients with Suspected Immune-Mediated Platelet Disorders: A Single-Center Study from Serbia [PDF]

Medicina
Background and Objectives: Alloantibodies directed against human platelet antigens and human leukocyte antigens are implicated in several immune-mediated platelet disorders, including platelet transfusion refractoriness, post-transfusion purpura and ...
Svetlana Vojvodić, Jasmina Grujić
doaj   +2 more sources

Transfusion efficacy and influencing factors of patients transfused with different therapeutic doses of platelets: a comparative analysis

Zhongguo shuxue zazhi
[Objective] To compare and analyze the efficacy of platelet transfusion in patients with different doses, and to analyze the risk factors for platelet transfusion refractoriness.
ZHU Jianling, CHENG Tingting, MA Chunya, FU Lihui, SHI Hongmei, YU Yang   +5 more
doaj   +2 more sources

Case Study: HLA incompatible platelet infusion to allow emergency salvage HCT in a patient with primary graft failure due to donor specific HLA antibody [PDF]

Frontiers in Immunology
A patient with myelodysplasia received a haploidentical hematopoietic stem cell transplant (HCT). Pre-transplant HLA antibody screening showed no detectable donor-specific antibodies (DSAs). Post-transplant, the patient developed an anti-HLA-A2 antibody,
Louise Goddard, Jonathan Moses, Gerard Joseph Chu, Robert P. Carroll   +3 more
doaj   +2 more sources

Research progress on prevention strategies for immune platelet transfusion refractoriness

Zhongguo shuxue zazhi
Platelet transfusion refractoriness (PTR) is a common issue among patients with hematological diseases and tumors. This article reviews the diagnostic criteria, influencing factors, and recent prevention and management strategies for immune PTR.
ZHAO Peizhe, XU Yi, LIANG Yajun, LI Qing, ZHOU Yuan, XU Xianguo   +5 more
doaj   +2 more sources

A case of platelet transfusion refractoriness in a CD36-negative patient with acute myeloid leukemia: Diagnostic and therapeutic management. [PDF]

Transfusion, 2022
To the Editor, CD36 deficiency is responsible for CD36 iso-immunizations following pregnancy causing fetal and neonatal alloimmune thrombocytopenia (FNAIT) and sometimes early fetal loss or platelet transfusion, inducing platelet transfusion ...
Pedini P, Hicheri Y, Bertand G, Dettori I, Basire A, Lazaygues C, Chabrières C, Perrin C, Pascal J, Chiaroni J, Renac V, Ladaique P, Vey N, Picard C.   +13 more
europepmc   +2 more sources

Platelet transfusion: basic aspects

Swiss Medical Weekly, 2013
Platelet transfusions have been shown to prevent major haemorrhage and improve survival in thrombocytopenic patients. Since then, advances in the preparation of platelet components, including the introduction of pathogen reduction techniques, have ...
Andreas Holbro, Laura Infanti, Jörg Sigle, Andreas Buser   +3 more
doaj   +2 more sources

Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis. [PDF]

Front Med (Lausanne), 2022
Platelet transfusion refractoriness (PTR) is common in patients with hematology and oncology and is becoming an important barrier in the treatment of thrombocytopenia and hemorrhage.
Liu Y, Zhang Y, Chen D, Fu Y.
europepmc   +2 more sources

Platelet HLA gene bank digital matching technology for platelet transfusion refractory patients with malignant tumors: a case report [PDF]

Frontiers in Oncology
The platelet human leucocyte antigen (HLA) gene bank contains the genetic information of HLA loci in a large number of blood donors. Currently, the most effective treatment for platelet transfusion refractoriness (PTR) is to evaluate the probability of ...
Xiang Gao, Jianhua Li, Xiuwen Ni, Lijun Wang, Peilin Hu, Xiaowei Zhu   +5 more
doaj   +2 more sources

Evaluation of Human Leucocyte Antigen Mediated Platelet Transfusion Refractoriness and Platelet Crossmatching Assay in Patients with Hematologic Disorders. [PDF]

Oman Med J, 2022
Objectives Platelet refractoriness complicates the platelet transfusion, which is essential for managing thrombocytopenia in patients with hematological disorders. It is associated with adverse clinical outcomes and increased health care costs.
Neanaey WA, Deghady AA, Nafea DA, Fahmy NM, Gouda AM.   +4 more
europepmc   +2 more sources

Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. [PDF]

Front Pharmacol, 2021
Background: Chimeric antigen receptor T cell (CAR-T) therapy is successful in improving treatment outcomes for relapsed/refractory acute lymphoblastic leukemia (R/R ALL). However, toxicities associated with CAR-T therapy are being increasingly identified.
Liu Y, Liang B, Liu Y, Wei G, Wu W, Yang L, Yang L, Huang H, Xie J, Hu Y.   +9 more
europepmc   +2 more sources